- Home
- VALN vs CRMD Comparison
VALN vs CRMD Comparison
Compare VALN & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALN
- CRMD
- Stock Information
- Founded
- VALN 2012
- CRMD 2006
- Country
- VALN France
- CRMD United States
- Employees
- VALN N/A
- CRMD N/A
- Industry
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- VALN Health Care
- CRMD Health Care
- Exchange
- VALN Nasdaq
- CRMD Nasdaq
- Market Cap
- VALN 777.9M
- CRMD 865.2M
- IPO Year
- VALN 2021
- CRMD 2010
- Fundamental
- Price
- VALN $10.44
- CRMD $10.81
- Analyst Decision
- VALN Strong Buy
- CRMD Strong Buy
- Analyst Count
- VALN 4
- CRMD 8
- Target Price
- VALN $15.75
- CRMD $17.57
- AVG Volume (30 Days)
- VALN 77.5K
- CRMD 2.4M
- Earning Date
- VALN 11-06-2025
- CRMD 10-29-2025
- Dividend Yield
- VALN N/A
- CRMD N/A
- EPS Growth
- VALN N/A
- CRMD N/A
- EPS
- VALN N/A
- CRMD 0.79
- Revenue
- VALN $230,566,060.00
- CRMD $121,484,498.00
- Revenue This Year
- VALN $15.69
- CRMD $480.51
- Revenue Next Year
- VALN $22.15
- CRMD $59.81
- P/E Ratio
- VALN N/A
- CRMD $13.33
- Revenue Growth
- VALN 25.47
- CRMD 14970.29
- 52 Week Low
- VALN $3.62
- CRMD $5.60
- 52 Week High
- VALN $12.25
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- VALN 51.09
- CRMD 40.31
- Support Level
- VALN $10.08
- CRMD $10.39
- Resistance Level
- VALN $11.35
- CRMD $11.71
- Average True Range (ATR)
- VALN 0.43
- CRMD 0.44
- MACD
- VALN -0.13
- CRMD -0.03
- Stochastic Oscillator
- VALN 29.25
- CRMD 18.64
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.